Redeye lowers its estimates on the back of I-Tech’s second quarter, which showed a surprising slowdo...
* A quarter centred on preparations * Orviglance FDA submission around the corner * Fair value range...
* Weaker Q2 due to natural quarterly variations * Cut '25e-'27e EBIT by 12-13% * Demand intact, rebo...
* Q2 sales +3% and EBITDA +4% vs. ABGSCe * We raise EBITDA by 1-4% and EBIT by 4-8% for '26e-'27e * ...
Redeye comments on Medivir’s Q2 report. The quarter was somewhat uneventful, but the company has mad...
* Sales SEK 6.5m, EBIT SEK -16m (vs. ABGSCe 11m and -12m) * No machine deliveries in the quarter (in...
Mendus’s Q225 results reflect a period of progress across the pipeline.
Nokian Panimo delivered a solid debut performance that met expectations despite challenging weather ...
Redeye comments on I-Tech’s Q2 figures that missed our expectations, driven by weaker sales.
Redeye comments on Sleep Cycle’s Q2 report, which was broadly in line with expectations.
* Q2: 3% sales growth, 1% adj. EBIT margin * '25e-'27e adj.
Redeye updates its estimates following Surgical Science’s Q2 2025 report, which aligned with the com...
Redeye comments on Oncopeptides’ 2nd quarter report, which saw significant sales progress in the cor...
Redeye provides its comment on Mendus’ Q2 2025 report.
Omsättningen sjönk till 6,6 (10,2) meur, varav PremierGaming stod för 5,8%.
